A phase III prospective, two-cohort non-randomized, multi-centre, multinational, open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer.

1. Signed written informed consent approved by the reviewing independent Ethics Committee;2. Female or male aged 18 years or above;3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;4. Histologically confirmed early invasive HER2-positive carcinoma of the breast with no evidence of residual, locally recurrent or metastatic disease and defined as clinical stage I (T1, N0, M0) to IIIC (any T, N3, M0) that is eligible for adjuvant treatment with trastuzumab.;Note: Patients treated without neoadjuvant or adjuvant chemotherapy, such as patients with low risk node negative tumours * 1.0 cm, elderly patients (>65 years of age) or patients with HER2-positive EBC but denying chemotherapy, will also be eligible to participate in the study, but their enrolment will be limited to approximately 10% of the total study population.;5. HER2-positive EBC, defined as IHC 3+, or a positive in situ hybridization (ISH testing) by validated and approved methods within a certified laboratory;6. Screening left ventricular ejection fraction (LVEF) * 55% as measured by echocardiography, Multi Gated Acquisition (MUGA) scan or Magnetic Resonance Imaging (MRI) per local practice.;7. Agreement to use an adequate, non-hormonal means of contraception by women of childbearing potential (defined as pre-menopausal and not surgically sterilized or <1 year after the onset of menopause) and by male participants with partners of childbearing potential only. Examples of adequate contraceptive measures are an intra-uterine device, a barrier method (condoms, diaphragm) in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are not acceptable for females participating in the study.;8. Intact skin at site of SC injection on the thigh.

Cancer Related Criteria;1. Previous neoadjuvant or adjuvant breast cancer treatment with an approved or investigational anti-HER2 agent;2. History of other malignancy which could affect compliance with the protocol or interpretation of results (including previous invasive ipsilateral or contralateral breast cancer). Patients with curatively treated carcinoma in situ of the cervix or basal cell carcinoma, and patients with other curatively-treated malignancies, other than breast cancer, who have been disease-free for at least 5 years, are eligible.;3. Past history of ductal carcinoma in situ (DCIS) within the last 5 years that has been treated with any systemic therapy OR with radiation therapy to the ipsilateral breast where invasive cancer subsequently develops. Patients who had their DCIS treated with surgery only are allowed to enter the study.;4. Metastatic disease;Haematological, Biochemical and Organ Function Related Criteria;5. Inadequate bone marrow function (as indicated by any of the following):;* Total white blood cell count < 2,500 / mm3 (<2.5 x 109/L);*Neutrophil count <1,500 / mm3 (<1.5 x 109/L);* Platelets <100,000 / mm3 (<100 x 109/L);* Haemoglobin <10 g/dL;6. Impaired hepatic function (as indicated by any of the following):;* Serum total bilirubin >1.5 x upper limit of normal (ULN);* Alanine amino transferase > 2.5 x ULN
* Aspartate amino transferase > 2.5 x ULN;* Alkaline phosphatase >2.5 x ULN;7. Impaired renal function: serum creatinine >1.5 x ULN;Other Study Drug Related Exclusion Criteria;8. Serious cardiac illness or medical conditions including but not confined to:;* History of documented heart failure or systolic dysfunction (LVEF <50%);* High-risk uncontrolled arrhythmias such as atrial tachycardia with a heart rate >100/min at rest, significant ventricular arrhythmia (ventricular tachycardia) or higher-grade atrioventricular (AV) block (second degree AV-block Type 2 [Mobitz 2] or third degree AV-block);* Angina pectoris requiring anti-anginal medication;* Clinically significant valvular heart disease;* Evidence of transmural infarction on electrocardiogram (ECG);* Poorly controlled or uncontrolled hypertension (blood pressure constantly over 140/90 mm/hg, despite treatment), or history of hypertensive crisis or hypertensive encephalopathy
9. Other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illness;10. Prior maximum cumulative dose of doxorubicin >360 mg/m2 or maximum cumulative dose of epirubicin >720 mg/m2 or equivalent;11. Known hypersensitivity to trastuzumab, murine proteins, or excipients, or a general hypersensitivity to adhesives (Cohort B only);12. History of severe allergic or immunological reactions, e.g. difficult to control asthma;General Exclusion Criteria;13. Pregnancy or lactation;14. Unable or unwilling to comply with the requirements of the protocol as assessed by the investigator;15. Concurrent enrolment in another clinical trial using an investigational anti-cancer treatment, including hormonal therapy, bisphosphonate therapy and immunotherapy, within 28 days prior to the first dose of study treatment;16. Major surgical procedure or significant traumatic injury within 14 days prior to the first dose of study treatment or anticipated need for major surgery during the course of study treatment except for breast cancer surgery for patient receiving study drug in the neoadjuvant setting. Patients must be free of any clinically significant sequalae of prior surgery before they can receive their first dose of study treatment.;17. More than 12 weeks between the end of the last chemotherapy cycle and the first dose of study treatment, in case these treatments are initiated sequentially. This criterion does not apply to patients who are starting trastuzumab SC without previous or concurrent chemotherapy or concurrently with chemotherapy.;18. Current peripheral neuropathy of grade 3 or greater per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0.